Osteoporosis is characterized by the weakening of bones, making them fragile and prone to breakage. Excessive activity of 'osteoclasts' or bone-absorbing cells leads to bone loss. Targeting osteoclast differentiation is therefore, a potential therapeutic strategy. In a new study, researchers have discovered a novel role of the Ctdnep1 phosphatase in suppressing osteoclast differentiation and bone resorption. The study provides novel insights into the process of bone remodeling and therapeutic targets.